A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

被引：0
|
作者：
J. P. Arnoletti
A. Frolov
M. Eloubeidi
K. Keene
J. Posey
T. Wood
Edward Greeno
N. Jhala
S. Varadarajulu
S. Russo
J. Christein
R. Oster
D. J. Buchsbaum
S. M. Vickers
机构：
[1] University of Alabama at Birmingham,Department of Surgery
[2] University of Alabama at Birmingham,Department of Gastroenterology
[3] University of Alabama at Birmingham,Department of Radiation Oncology
[4] University of Alabama at Birmingham,Department of Medical Oncology
[5] University of Minnesota,Division of Hematology, Oncology and Transplantation
[6] University of Alabama at Birmingham,Department of Pathology
[7] East Carolina University,Department of Radiation Oncology
[8] University of Alabama at Birmingham,Department of Biostatistics
[9] University of Minnesota, Surgery Department
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Cetuximab; Gemcitabine; Radiation therapy; Pancreatic cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：891 / 897
页数：6
相关论文
共 50 条
  • [1] A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer
    Arnoletti, J. P.
    Frolov, A.
    Eloubeidi, M.
    Keene, K.
    Posey, J.
    Wood, T.
    Greeno, Edward
    Jhala, N.
    Varadarajulu, S.
    Russo, S.
    Christein, J.
    Oster, R.
    Buchsbaum, D. J.
    Vickers, S. M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 891 - 897
  • [2] Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Strumberg, Dirk
    Schultheis, Beate
    Scheulen, M. E.
    Hilger, R. A.
    Krauss, J.
    Marschner, N.
    Lordick, F.
    Bach, F.
    Reuter, D.
    Edler, L.
    Mross, K.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1138 - 1143
  • [3] Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Dirk Strumberg
    Beate Schultheis
    M. E. Scheulen
    R. A. Hilger
    J. Krauss
    N. Marschner
    F. Lordick
    F. Bach
    D. Reuter
    L. Edler
    K. Mross
    Investigational New Drugs, 2012, 30 : 1138 - 1143
  • [4] Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Strumberg, D.
    Schultheis, B.
    Scheulen, M. E.
    Hilger, R. A.
    Krauss, J.
    Marschner, N.
    Lordick, F.
    Bach, F.
    Reuter, D.
    Edler, L.
    Mross, K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (07) : 473 - 475
  • [5] Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver
    Huang, Tsai-Wang
    Wang, Chih-Hsin
    Hsieh, Chung-Bao
    ONKOLOGIE, 2007, 30 (03): : 129 - 131
  • [6] Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
    Martinelli, Erika
    Orditura, Michele
    De Vita, Ferdinando
    Galizia, Gennaro
    Ciardiello, Fortunato
    CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 242 - 248
  • [7] Anti-Epidermal Growth Factor Receptor Treatment Strategies in Advanced Pancreatic Cancer: Success or Failure?
    Boeck, Stefan
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : E70 - E71
  • [8] Role of an anti-epidermal growth factor receptor in treating cancer
    Waksal, HW
    CANCER AND METASTASIS REVIEWS, 1999, 18 (04) : 427 - 436
  • [9] Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer
    Harlan W. Waksal
    Cancer and Metastasis Reviews, 1999, 18 : 427 - 436
  • [10] Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
    G Galizia
    E Lieto
    F De Vita
    M Orditura
    P Castellano
    T Troiani
    V Imperatore
    F Ciardiello
    Oncogene, 2007, 26 : 3654 - 3660
12345